177 related articles for article (PubMed ID: 23238661)
41. The impact of cystic fibrosis-related diabetes on health-related quality of life.
Kwong E; Desai S; Chong L; Lee K; Zheng J; Wilcox PG; Quon BS
J Cyst Fibros; 2019 Sep; 18(5):734-736. PubMed ID: 30935840
[TBL] [Abstract][Full Text] [Related]
42. Screening for cystic fibrosis-related diabetes: a systematic review.
Waugh N; Royle P; Craigie I; Ho V; Pandit L; Ewings P; Adler A; Helms P; Sheldon C
Health Technol Assess; 2012; 16(24):iii-iv, 1-179. PubMed ID: 22572153
[TBL] [Abstract][Full Text] [Related]
43. Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?
Zorron M; Marson FAL; Morcillo AM; Gonçalves AC; El Beck MS; Ribeiro JD; Ribeiro AF
J Bras Pneumol; 2022; 48(2):e20210307. PubMed ID: 35475864
[TBL] [Abstract][Full Text] [Related]
44. Glucose tolerance affects pubertal growth and final height of children with cystic fibrosis.
Bizzarri C; Montemitro E; Pedicelli S; Ciccone S; Majo F; Cappa M; Lucidi V
Pediatr Pulmonol; 2015 Feb; 50(2):144-9. PubMed ID: 24678051
[TBL] [Abstract][Full Text] [Related]
45. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.
Gaines H; Jones KR; Lim J; Medhi NF; Chen S; Scofield RH
J Diabetes Complications; 2021 Jun; 35(6):107845. PubMed ID: 33558149
[TBL] [Abstract][Full Text] [Related]
46. Decreasing the Time to Insulin Administration for Hospitalized Patients With Cystic Fibrosis-Related Diabetes.
Smego A; Lawson S; Courter JD; Warden D; Corathers S
Hosp Pediatr; 2018 May; 8(5):288-292. PubMed ID: 29691278
[TBL] [Abstract][Full Text] [Related]
47. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry.
Sandig D; Grimsmann J; Reinauer C; Melmer A; Zimny S; Müller-Korbsch M; Forestier N; Zeyfang A; Bramlage P; Danne T; Meissner T; Holl RW
Diabetes Technol Ther; 2020 Aug; 22(8):602-612. PubMed ID: 32522039
[No Abstract] [Full Text] [Related]
48. Cystic fibrosis related diabetes mellitus - diagnostic and management challenges.
Lek N; Acerini CL
Curr Diabetes Rev; 2010 Jan; 6(1):9-16. PubMed ID: 20034372
[TBL] [Abstract][Full Text] [Related]
49. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review.
Golden SH; Sapir T
J Manag Care Pharm; 2012 Aug; 18(6 Suppl):S1-17. PubMed ID: 22984955
[TBL] [Abstract][Full Text] [Related]
50. Improving screening for cystic fibrosis-related diabetes at a pediatric cystic fibrosis program.
Kern AS; Prestridge AL
Pediatrics; 2013 Aug; 132(2):e512-8. PubMed ID: 23821699
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of glucose intolerance in cystic fibrosis.
Mohan K; Miller H; Dyce P; Grainger R; Hughes R; Vora J; Ledson M; Walshaw M
Diabet Med; 2009 Jun; 26(6):582-8. PubMed ID: 19538232
[TBL] [Abstract][Full Text] [Related]
52. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries.
Maahs DM; Hermann JM; DuBose SN; Miller KM; Heidtmann B; DiMeglio LA; Rami-Merhar B; Beck RW; Schober E; Tamborlane WV; Kapellen TM; Holl RW; ;
Diabetologia; 2014 Aug; 57(8):1578-85. PubMed ID: 24893863
[TBL] [Abstract][Full Text] [Related]
53. [Cystic fibrosis-related diabetes: a frequent co-morbidity].
Della Manna T; Setian N; Rodrigues JC
Arq Bras Endocrinol Metabol; 2008 Mar; 52(2):188-97. PubMed ID: 18438529
[TBL] [Abstract][Full Text] [Related]
54. Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
Shalitin S; Gil M; Nimri R; de Vries L; Gavan MY; Phillip M
Diabet Med; 2010 Mar; 27(3):339-47. PubMed ID: 20536498
[TBL] [Abstract][Full Text] [Related]
55. Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits.
Aksit MA; Pace RG; Vecchio-Pagán B; Ling H; Rommens JM; Boelle PY; Guillot L; Raraigh KS; Pugh E; Zhang P; Strug LJ; Drumm ML; Knowles MR; Cutting GR; Corvol H; Blackman SM
J Clin Endocrinol Metab; 2020 May; 105(5):1401-15. PubMed ID: 31697830
[TBL] [Abstract][Full Text] [Related]
56. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries.
van Mark G; Lanzinger S; Sziegoleit S; Putz FJ; Durmaz M; Borscheller M; Danne T; Seufert J; Holl RW; Bramlage P
Adv Ther; 2019 Jul; 36(7):1628-1641. PubMed ID: 31119688
[TBL] [Abstract][Full Text] [Related]
57. Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control.
Hörtenhuber T; Kiess W; Fröhlich-Reiterer E; Raile K; Stachow R; Bollow E; Rami-Merhar B; Holl RW;
Pediatr Diabetes; 2018 Jun; 19(4):727-732. PubMed ID: 29218837
[TBL] [Abstract][Full Text] [Related]
58. Increased detection of cystic-fibrosis-related diabetes in Australia.
Rana M; Munns CF; Selvadurai HC; Simonds S; Cooper PJ; Woodhead HJ; Hameed S; Verge CF; Lafferty AR; Crock PA; Craig ME
Arch Dis Child; 2011 Sep; 96(9):823-6. PubMed ID: 21653750
[TBL] [Abstract][Full Text] [Related]
59. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
[TBL] [Abstract][Full Text] [Related]
60. Improved metabolic control in children and adolescents with type 1 diabetes: a trend analysis using prospective multicenter data from Germany and Austria.
Rosenbauer J; Dost A; Karges B; Hungele A; Stahl A; Bächle C; Gerstl EM; Kastendieck C; Hofer SE; Holl RW;
Diabetes Care; 2012 Jan; 35(1):80-6. PubMed ID: 22074726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
